TBPH

THERAVANCE BIOPHARMA, INC.

TBPH · CIK 1583107 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$19M
20172024
Net Income−$16M
20172024
Operating CF−$12M
20172024
Free Cash Flow
20172024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.0B$0.0B$0.1B$0.2B$0.3B$0.2B$0.2B$0.2B
SG&A Expense$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
Operating Income$-0.0B$-0.0B$-0.0B$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B
Net Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.1B$-0.1B$-0.1B$-0.1B
EPS (Basic)$-0.31$-0.17$-0.15$-0.43————
EPS (Diluted)$-0.31$-0.17$-0.15$-0.43————

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.4B$0.4B$0.6B$0.4B$0.5B$0.4B$0.6B$0.4B
Current Assets$0.2B$0.1B$0.4B$0.2B$0.4B$0.3B$0.5B$0.4B
Cash & Equivalents$0.0B$0.0B$0.3B$0.1B$0.1B$0.1B$0.4B$0.1B
Total Liabilities————————
Current Liabilities$0.0B$0.0B$0.0B$0.1B$0.1B$0.1B$0.1B$0.1B
Stockholders' Equity$0.2B$0.2B$0.4B$-0.3B$-0.3B$-0.2B$-0.1B$0.1B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.0B$-0.0B$-0.2B$-0.2B$-0.3B$-0.2B$-0.1B$-0.2B
Investing Cash Flow$0.0B$-0.0B$1.2B$0.1B$0.0B$-0.1B$0.2B$-0.1B
Capital Expenditures————————
Financing Cash Flow$-0.0B$-0.2B$-0.8B$0.1B$0.3B$0.0B$0.2B$0.0B
← Companies